KRAS and malignant colon neoplasm: In a retrospective study evaluating the effectiveness of cetuximab added to FOLFOX treatment in adjuvant therapy in patients diagnosed with stage III colon cancer, it was shown that while KRAS mutation was a poor prognostic marker in MSS tumors, it was not a prognostic marker in MSI tumors [73].